Glucocorticoid and proteasome inhibitor impact on the leukemic lymphoblast: Multiple, diverse signals converging on a few key downstream regulators

Molecular and Cellular Endocrinology

Volumn 351, Issue 2, 2012, Pages 142-151

  Lambrou, George I ^a   Papadimitriou, Lina ^a,b   Chrousos, George P ^a,b   Vlahopoulos, Spiros A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Glucocorticoid; Leukemia; Lymphoblast; Proteasome inhibitor

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CARFILZOMIB; GAMMA SECRETASE INHIBITOR; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR BETA; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OBATOCLAX; PREDNISOLONE; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN MCL 1; STAT3 PROTEIN; TRANSCRIPTION FACTOR RELA; TUMOR SUPPRESSOR PROTEIN; VORINOSTAT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CELL FATE; CHILDHOOD LEUKEMIA; DEGENERATIVE DISEASE; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; DRUG TARGETING; ENZYME INHIBITION; GENE; GENE FUNCTION; GENETIC HETEROGENEITY; HEMATOLOGIC MALIGNANCY; HUMAN; INTRACELLULAR SIGNALING; LEUKEMIA CELL LINE; LYMPHOBLAST; MCL 1 GENE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE MYELOMA; NONHUMAN; ONCOGENE C MYC; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; T CELL LEUKEMIA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; GLUCOCORTICOIDS; HUMANS; LEUKEMIA; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION;

EID: 84857142727     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.01.003     Document Type: Review

References (97)

1. Adams R.A., Pothier L., Flowers A., Lazarus H., Farber S., Foley G.E. The question of stemlines in human acute leukemia. Comparison of cells isolated in vitro and in vivo from a patient with acute lymphoblastic leukemia. Exp. Cell Res. 1970, 62:5-10.
2. Alarcon-Vargas D., Ronai Z. C-Jun-NH2 kinase (JNK) contributes to the regulation of c-Myc protein stability. J. Biol. Chem. 2004, 279:5008-5016.
3. Bachmann P.S., Piazza R.G., Janes M.E., Wong N.C., Davies C., Mogavero A., Bhadri V.A., Szymanska B., Geninson G., Magistroni V., Cazzaniga G., Biondi A., Miranda-Saavedra D., Göttgens B., Saffery R., Craig J.M., Marshall G.M., Gambacorti-Passerini C., Pimanda J.E., Lock R.B. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood 2010, 116:3013-3022.
4. Baud V., Derudder E. Control of NF-κB activity by proteolysis. Curr. Top. Microbiol. Immunol. 2011, 349:97-114.
5. Baumgartner B., Weber M., Quirling M., Fischer C., Page S., Adam M., Von Schilling C., Waterhouse C., Schmid C., Neumeier D., Brand K. Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts. Leukemia 2002, 16:2062-2071.
6. Beesley A.H., Firth M.J., Ford J., Weller R.E., Freitas J.R., Perera K.U., Kees U.R. Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism. Br. J. Cancer 2009, 100:1926-1936.
7. Biddie S.C., John S., Sabo P.J., Thurman R.E., Johnson T.A., Schiltz R.L., Miranda T.B., Sung M.-H., Trump S., Lightman S.L., Vinson C., Stamatoyannopoulos J.A., Hager G.L. Transcription factor AP1 potentiates chromatin accessibility and glucocorticoid receptor binding. Mol. Cell 2011, 43:145-155.
8. Blanco T.M., Mantalaris A., Bismarck A., Panoskaltsis N. The development of a three-dimensional scaffold for ex vivo biomimicry of human acute myeloid leukaemia. Biomaterials 2010, 31:2243-2251.
9. Bourquin J.-P., Bornhauser B. Have chemosensitizing strategies for multidrug-resistant childhood acute lymphoblastic leukemia come of age?. Expert. Rev. Hematol. 2010, 3:369-372.
10. Buoso E., Lanni C., Schettini G., Govoni S., Racchi M. Beta-amyloid precursor protein metabolism: focus on the functions and degradation of its intracellular domain. Pharmacol. Res. 2010, 62:308-317.
11. Campbell K.J., Bath M.L., Turner M.L., Vandenberg C.J., Bouillet P., Metcalf D., Scott C.L., Cory S. Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance. Blood 2010, 116:3197-3207.
12. Castro-Caldas M., Mendes A.F., Carvalho A.P., Duarte C.B., Lopes M.C. Dexamethasone prevents interleukin-1beta-induced nuclear factor-kappaB activation by upregulating IkappaB-alpha synthesis, in lymphoblastic cells. Mediators Inflamm. 2003, 12:37-46.
13. Chang P.-Y., Draheim K., Kelliher M.A., Miyamoto S. NFKB1 is a direct target of the TAL1 oncoprotein in human T leukemia cells. Cancer Res. 2006, 66:6008-6013.
14. Chen S., Blank J.L., Peters T., Liu X.J., Rappoli D.M., Pickard M.D., Menon S., Yu J., Driscoll D.L., Lingaraj T., Burkhardt A.L., Chen W., Garcia K., Sappal D.S., Gray J., Hales P., Leroy P.J., Ringeling J., Rabino C., Spelman J.J., Morgenstern J.P., Lightcap E.S. Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Res. 2010, 70:4318-4326.
15. Chrousos, G.P., Kino, T., 2005. Intracellular glucocorticoid signaling: a formerly simple system turns stochastic. Sci. STKE 2005, pe48.
16. Cidlowski J.A., King K.L., Evans-Storms R.B., Montague J.W., Bortner C.D., Hughes F.M. The biochemistry and molecular biology of glucocorticoid-induced apoptosis in the immune system. Recent Prog. Horm. Res. 1996, 51:457-490. (Discussion 490-491).
17. Copland J.A., Sheffield-Moore M., Koldzic-Zivanovic N., Gentry S., Lamprou G., Tzortzatou-Stathopoulou F., Zoumpourlis V., Urban R.J., Vlahopoulos S.A. Sex steroid receptors in skeletal differentiation and epithelial neoplasia: is tissue-specific intervention possible?. Bioessays 2009, 31:629-641.
18. Csizmadia V., Raczynski A., Csizmadia E., Fedyk E.R., Rottman J., Alden C.L. Effect of an experimental proteasome inhibitor on the cytoskeleton, cytosolic protein turnover, and induction in the neuronal cells in vitro. Neurotoxicology 2008, 29:232-243.
19. Curry J.D., Smith M.T. Measurement of SIL-TAL1 fusion gene transcripts associated with human T-cell lymphocytic leukemia by real-time reverse transcriptase-PCR. Leukotriene Res. 2003, 27:575-582.
20. Dallaporta B., Pablo M., Maisse C., Daugas E., Loeffler M., Zamzami N., Kroemer G. Proteasome activation as a critical event of thymocyte apoptosis. Cell Death Differ. 2000, 7:368-373.
21. Dick L.R., Fleming P.E. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov. Today 2010, 15:243-249.
22. Driscoll J.J., Minter A., Driscoll D.A., Burris J.K. The ubiquitin+proteasome protein degradation pathway as a therapeutic strategy in the treatment of solid tumor malignancies. Anticancer Agents Med. Chem. 2011, 11:242-246.
23. Dunleavy K., Pittaluga S., Czuczman M.S., Dave S.S., Wright G., Grant N., Shovlin M., Jaffe E.S., Janik J.E., Staudt L.M., Wilson W.H. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009, 113:6069-6076.
24. Feinman R., Koury J., Thames M., Barlogie B., Epstein J., Siegel D.S. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 1999, 93:3044-3052.
25. Foley G.E., Lazarus H., Farber S., Uzman B.G., Boone B.A., McCarthy R.E. Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 1965, 18:522-529.
26. Garza A.S., Miller A.L., Johnson B.H., Thompson E.B. Converting cell lines representing hematological malignancies from glucocorticoid-resistant to glucocorticoid-sensitive: signaling pathway interactions. Leukotriene Res. 2009, 33:717-727.
27. Gerondakis S., Siebenlist U. Roles of the NF-kappaB pathway in lymphocyte development and function. Cold Spring Harb. Perspect. Biol. 2010, 2:a000182.
28. Gil L., Styczynski J., Dytfeld D., Debski R., Kazmierczak M., Kolodziej B., Rafinska B., Kubicka M., Nowicki A., Komarnicki M., Wysocki M. Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia. Anticancer Res. 2007, 27:4021-4025.
29. Graux C. Biology of acute lymphoblastic leukemia (ALL): clinical and therapeutic relevance. Transfus. Apher. Sci. 2011, 44:183-189.
30. Gutiérrez M.I., Siraj A.K., Ibrahim M.M., Hussain A., Bhatia K. Childhood and adult ALL: differences in epigenetic lesions associated with cell cycle genes. Am. J. Hematol. 2005, 80:158-160.
31. Guzman M.L., Neering S.J., Upchurch D., Grimes B., Howard D.S., Rizzieri D.A., Luger S.M., Jordan C.T. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001, 98:2301-2307.
32. Guzman M.L., Swiderski C.F., Howard D.S., Grimes B.A., Rossi R.M., Szilvassy S.J., Jordan C.T. Preferential induction of apoptosis for primary human leukemic stem cells. Proc. Natl. Acad. Sci. USA 2002, 99:16220-16225.
33. Han B.-W., Feng D.-D., Li Z.-G., Luo X.-Q., Zhang H., Li X.-J., Zhang X.-J., Zheng L.-L., Zeng C.-W., Lin K.-Y., Zhang P., Xu L., Chen Y.-Q. A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL. Hum. Mol. Genet. 2011, 20:4903-4915.
34. Han J., Goldstein L.A., Hou W., Gastman B.R., Rabinowich H. Regulation of mitochondrial apoptotic events by p53-mediated disruption of complexes between antiapoptotic Bcl-2 members and Bim. J. Biol. Chem. 2010, 285:22473-22483.
35. Han Y., Weinman S., Boldogh I., Walker R.K., Brasier A.R. Tumor necrosis factor-alpha-inducible IkappaBalpha proteolysis mediated by cytosolic m-calpain. A mechanism parallel to the ubiquitin-proteasome pathway for nuclear factor-kappa b activation. J. Biol. Chem. 1999, 274:787-794.
36. Hassane D.C., Guzman M.L., Corbett C., Li X., Abboud R., Young F., Liesveld J.L., Carroll M., Jordan C.T. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood 2008, 111:5654-5662.
37. Hatfield K., Ryningen A., Corbascio M., Bruserud O. Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts. Int. J. Cancer 2006, 119:2313-2321.
38. Horton T.M., Gannavarapu A., Blaney S.M., D'Argenio D.Z., Plon S.E., Berg S.L. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother. Pharmacol. 2006, 58:13-23.
39. Horton T.M., Pati D., Plon S.E., Thompson P.A., Bomgaars L.R., Adamson P.C., Ingle A.M., Wright J., Brockman A.H., Paton M., Blaney S.M. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a children's oncology group study. Clin. Cancer Res. 2007, 13:1516-1522.
40. Houghton P.J., Morton C.L., Kolb E.A., Lock R., Carol H., Reynolds C.P., Keshelava N., Maris J.M., Keir S.T., Wu J., Smith M.A. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr. Blood Cancer 2008, 50:37-45.
41. Ichijo T., Chrousos G.P., Kino T. Activated glucocorticoid receptor interacts with the INHAT component Set/TAF-Ibeta and releases it from a glucocorticoid-responsive gene promoter, relieving repression: implications for the pathogenesis of glucocorticoid resistance in acute undifferentiated leukemia with Set-Can translocation. Mol. Cell. Endocrinol. 2008, 283:19-31.
42. Inuzuka H., Fukushima H., Shaik S., Liu P., Lau A.W., Wei W. Mcl-1 ubiquitination and destruction. Oncotarget 2011, 2:239-244.
43. Jagannath S., Richardson P.G., Barlogie B., Berenson J.R., Singhal S., Irwin D., Srkalovic G., Schenkein D.P., Esseltine D.L., Anderson K.C. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006, 91:929-934.
44. Jatiani S.S., Baker S.J., Silverman L.R., Reddy E.P. Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer 2010, 1:979-993.
45. Jiang X., Tsang Y.H., Yu Q. C-Myc overexpression sensitizes Bim-mediated Bax activation for apoptosis induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through regulating Bcl-2/Bcl-xL expression. Int. J. Biochem. Cell Biol. 2007, 39:1016-1025.
46. Kaspers G.J., Pieters R., Klumper E., de Waal F.C., Veerman A.J. The treatment of recurrence in children with acute lymphatic leukemia. Current results and various developments. Tijdschr Kindergeneeskd 1993, 61:1-7.
47. De Keersmaecker K., Lahortiga I., Mentens N., Folens C., Van Neste L., Bekaert S., Vandenberghe P., Odero M.D., Marynen P., Cools J. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia. Haematologica 2008, 93:533-542.
48. Kordes U., Krappmann D., Heissmeyer V., Ludwig W.D., Scheidereit C. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000, 14:399-402.
49. Kortylewski M., Xin H., Kujawski M., Lee H., Liu Y., Harris T., Drake C., Pardoll D., Yu H. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009, 15:114-123.
50. Lambrou G.I., Vlahopoulos S., Papathanasiou C., Papanikolaou M., Karpusas M., Zoumakis E., Tzortzatou-Stathopoulou F. Prednisolone exerts late mitogenic and biphasic effects on resistant acute lymphoblastic leukemia cells: relation to early gene expression. Leukotriene Res. 2009, 33:1684-1695.
51. Lee H., Herrmann A., Deng J.-H., Kujawski M., Niu G., Li Z., Forman S., Jove R., Pardoll D.M., Yu H. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009, 15:283-293.
52. Levitzki A., Klein S. Signal transduction therapy of cancer. Mol. Aspects Med. 2010, 31:287-329.
53. Liu S., Breit S., Danckwardt S., Muckenthaler M.U., Kulozik A.E. Downregulation of Notch signaling by gamma-secretase inhibition can abrogate chemotherapy-induced apoptosis in T-ALL cell lines. Ann. Hematol. 2009, 88:613-621.
54. Löffler M., Ausserlechner M.J., Tonko M., Hartmann B.L., Bernhard D., Geley S., Helmberg A., Kofler R. C-Myc does not prevent glucocorticoid-induced apoptosis of human leukemic lymphoblasts. Oncogene 1999, 18:4626-4631.
55. Lozzio C.B., Lozzio B.B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975, 45:321-334.
56. Luecke H.F., Yamamoto K.R. The glucocorticoid receptor blocks P-TEFb recruitment by NFkappaB to effect promoter-specific transcriptional repression. Genes Dev. 2005, 19:1116-1127.
57. Lynch J.T., Rajendran R., Xenaki G., Berrou I., Demonacos C., Krstic-Demonacos M. The role of glucocorticoid receptor phosphorylation in Mcl-1 and NOXA gene expression. Mol. Cancer 2010, 9:38.
58. Manabe A., Ohara A., Hasegawa D., Koh K., Saito T., Kiyokawa N., Kikuchi A., Takahashi H., Ikuta K., Hayashi Y., Hanada R., Tsuchida M. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo children's cancer study group study L99-15. Haematologica 2008, 93:1155-1160.
59. Medh R.D., Saeed M.F., Johnson B.H., Thompson E.B. Resistance of human leukemic CEM-C1 cells is overcome by synergism between glucocorticoid and protein kinase A pathways: correlation with c-Myc suppression. Cancer Res. 1998, 58:3684-3693.
60. Medh R.D., Wang A., Zhou F., Thompson E.B. Constitutive expression of ectopic c-Myc delays glucocorticoid-evoked apoptosis of human leukemic CEM-C7 cells. Oncogene 2001, 20:4629-4639.
61. Messinger Y., Gaynon P., Raetz E., Hutchinson R., Dubois S., Glade-Bender J., Sposto R., van der Giessen J., Eckroth E., Bostrom B.C. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr. Blood Cancer 2010, 55:254-259.
62. Mittal S., Dubey D., Yamakawa K., Ganesh S. Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment. Hum. Mol. Genet. 2007, 16:753-762.
63. Naderi E.H., Jochemsen A.G., Blomhoff H.K., Naderi S. Activation of cAMP signaling interferes with stress-induced p53 accumulation in ALL-derived cells by promoting the interaction between p53 and HDM2. Neoplasia 2011, 13:653-663.
64. Nakaya A., Sagawa M., Muto A., Uchida H., Ikeda Y., Kizaki M. The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-κB activity. Leukotriene Res. 2011, 35:243-249.
65. Nawrocki S.T., Carew J.S., Maclean K.H., Courage J.F., Huang P., Houghton J.A., Cleveland J.L., Giles F.J., McConkey D.J. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood 2008, 112:2917-2926.
66. Nowak D.E., Tian B., Jamaluddin M., Boldogh I., Vergara L.A., Choudhary S., Brasier A.R. RelA Ser276 phosphorylation is required for activation of a subset of NF-kappaB-dependent genes by recruiting cyclin-dependent kinase 9/cyclin T1 complexes. Mol. Cell. Biol. 2008, 28:3623-3638.
67. + thymocyte line. J. Immunol. 1998, 160:3835-3843.
68. Orban Z., Mitsiades N., Burke T.R., Tsokos M., Chrousos G.P. Caffeic acid phenethyl ester induces leukocyte apoptosis, modulates nuclear factor-kappa B and suppresses acute inflammation. Neuroimmunomodulation 2000, 7:99-105.
69. Pedersen I.M., Kitada S., Leoni L.M., Zapata J.M., Karras J.G., Tsukada N., Kipps T.J., Choi Y.S., Bennett F., Reed J.C. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002, 100:1795-1801.
70. Pérez-Galán P., Roué G., López-Guerra M., Nguyen M., Villamor N., Montserrat E., Shore G.C., Campo E., Colomer D. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia 2008, 22:1712-1720.
71. Ramdas J., Harmon J.M. Glucocorticoid-induced apoptosis and regulation of NF-kappaB activity in human leukemic T cells. Endocrinology 1998, 139:3813-3821.
72. Roué G., Pérez-Galán P., Mozos A., López-Guerra M., Xargay-Torrent S., Rosich L., Saborit-Villarroya I., Normant E., Campo E., Colomer D. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood 2011, 117:1270-1279.
73. Sagi S.A., Lessard C.B., Winden K.D., Maruyama H., Koo J.C., Weggen S., Kukar T.L., Golde T.E., Koo E.H. Substrate sequence influences γ-secretase modulator activity, role of the transmembrane domain of the amyloid precursor protein. J. Biol. Chem. 2011, 286:39794-39803.
74. Sasaki C.Y., Barberi T.J., Ghosh P., Longo D.L. Phosphorylation of RelA/p65 on serine 536 defines an I{kappa}B{alpha}-independent NF-{kappa}B pathway. J. Biol. Chem. 2005, 280:34538-34547.
75. Schmidt J., Metselaar J.M., Wauben M.H.M., Toyka K.V., Storm G., Gold R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 2003, 126:1895-1904.
76. Schotte D., Chau J.C.K., Sylvester G., Liu G., Chen C., van der Velden V.H.J., Broekhuis M.J.C., Peters T.C.J.M., Pieters R., den Boer M.L. Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia 2009, 23:313-322.
77. + hematopoietic cells. Cell Death Differ. 2007, 14:378-380.
78. Sionov R.V., Spokoini R., Kfir-Erenfeld S., Cohen O., Yefenof E. Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis. Adv. Cancer Res. 2008, 101:127-248.
79. Smith K.N., Lim J.-M., Wells L., Dalton S. Myc orchestrates a regulatory network required for the establishment and maintenance of pluripotency. Cell Cycle 2011, 10:592-597.
80. Stam R.W., Den Boer M.L., Schneider P., de Boer J., Hagelstein J., Valsecchi M.G., de Lorenzo P., Sallan S.E., Brady H.J.M., Armstrong S.A., Pieters R. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. Blood 2010, 115:1018-1025.
81. Tao Y., Williams-Skipp C., Scheinman R.I. Mapping of glucocorticoid receptor DNA binding domain surfaces contributing to transrepression of NF-kappa B and induction of apoptosis. J. Biol. Chem. 2001, 276:2329-2332.
82. Thompson E.B., Webb M.S., Miller A.L., Fofanov Y., Johnson B.H. Identification of genes leading to glucocorticoid-induced leukemic cell death. Lipids 2004, 39:821-825.
83. Tiberio L., Maier J.A., Schiaffonati L. Down-modulation of c-myc expression by phorbol ester protects CEM T leukaemia cells from starvation-induced apoptosis: role of ornithine decarboxylase and polyamines. Cell Death Differ. 2001, 8:967-976.
84. Tissing W.J.E., den Boer M.L., Meijerink J.P.P., Menezes R.X., Swagemakers S., van der Spek P.J., Sallan S.E., Armstrong S.A., Pieters R. Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. Blood 2007, 109:3929-3935.
85. Tissing W.J.E., Meijerink J.P.P., Brinkhof B., Broekhuis M.J.C., Menezes R.X., den Boer M.L., Pieters R. Glucocorticoid-induced glucocorticoid-receptor expression and promoter usage is not linked to glucocorticoid resistance in childhood ALL. Blood 2006, 108:1045-1049.
86. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 2000, 355:248-250.
87. Vacca A., Felli M.P., Palermo R., Di Mario G., Calce A., Di Giovine M., Frati L., Gulino A., Screpanti I. Notch3 and pre-TCR interaction unveils distinct NF-kappaB pathways in T-cell development and leukemia. EMBO J. 2006, 25:1000-1008.
88. Vilimas T., Mascarenhas J., Palomero T., Mandal M., Buonamici S., Meng F., Thompson B., Spaulding C., Macaroun S., Alegre M.-L., Kee B.L., Ferrando A., Miele L., Aifantis I. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat. Med. 2007, 13:70-77.
89. Vlahopoulos S., Boldogh I., Casola A., Brasier A.R. Nuclear factor-kappaB-dependent induction of interleukin-8 gene expression by tumor necrosis factor alpha: evidence for an antioxidant sensitive activating pathway distinct from nuclear translocation. Blood 1999, 94:1878-1889.
90. Vlahopoulos S., Zoumpourlis V.C. JNK: a key modulator of intracellular signaling. Biochem. Mosc. 2004, 69:844-854.
91. Wada M., Kosaka M., Saito S., Sano T., Tanaka K., Ichihara A. Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance. J. Lab. Clin. Med. 1993, 121:215-223.
92. Wang Z., Malone M.H., He H., McColl K.S., Distelhorst C.W. Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J. Biol. Chem. 2003, 278:23861-23867.
93. Watanabe T., Nagase K., Chosa M., Tobinai K. Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy. Br. J. Cancer 2010, 103:1580-1587.
94. Williamson M.J., Silva M.D., Terkelsen J., Robertson R., Yu L., Xia C., Hatsis P., Bannerman B., Babcock T., Cao Y., Kupperman E. The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models. Mol. Cancer Ther. 2009, 8:3234-3243.
95. Wuerzberger-Davis S.M., Chen Y., Yang D.T., Kearns J.D., Bates P.W., Lynch C., Ladell N.C., Yu M., Podd A., Zeng H., Huang T.T., Wen R., Hoffmann A., Wang D., Miyamoto S. Nuclear export of the NF-κB inhibitor IκBα is required for proper B cell and secondary lymphoid tissue formation. Immunity 2011, 34:188-200.
96. Xie Y. Structure, assembly and homeostatic regulation of the 26S proteasome. J. Mol. Cell Biol. 2010, 2:308-317.
97. Yu H., Jove R. The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 2004, 4:97-105.